Lausanne, Switzerland, October 17, 2019
ADC THERAPEUTICS DOSES FIRST PATIENTS IN PIVOTAL PHASE 2 CLINICAL TRIAL OF ADCT-301 IN PATIENTS WITH RELAPSED OR REFRACTORY HODGKIN LYMPHOMA
– ADC Therapeutics SA, a clinical-stage oncology-focused biotechnology company pioneering the development of highly potent and targeted antibody drug conjugates (ADCs) for patients suffering from hematological malignancies and solid tumors, today announced that the first patients have been dosed in a 100-patient pivotal Phase 2 clinical trial evaluating the efficacy and safety of ADCT-301 (camidanlumab tesirine) in patients with relapsed or refractory Hodgkin lymphoma (HL). The trial is intended to support the submission of a Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA).
Alex Herrera, MD, Assistant Professor, Department of Hematology/Hematopoietic Cell Transplantation at City of Hope Medical Center and an investigator for the trial, said, “Approximately 15 to 25 percent of the 16,500 patients diagnosed with HL each year in the U.S. and Europe have relapsed or refractory HL. While advances have been made in the treatment of HL, a significant unmet medical need remains in the relapsed or refractory HL patient population, especially patients who have progressed following treatment with other novel agents. I believe ADCT-301 has the potential to fill this important medical need.”